Carlos A Valencia-Hernández1, Joni V Lindbohm1,2, Martin J Shipley1, Ian B Wilkinson3, Carmel M McEniery3, Sara Ahmadi-Abhari4, Archana Singh-Manoux1,5, Mika Kivimäki1, Eric J Brunner1. 1. Research Department of Epidemiology and Public Health, University College London, London, United Kingdom (C.A.V.-H., J.V. L., M.J.S., A.S.-M., M.K., E.J.B.). 2. Clinicum, Department of Public Health, University of Helsinki (J.V.L.). 3. Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (I.B.W., C.M.M.). 4. Ageing Epidemiology Research Unit, Imperial College London, United Kingdom (S.A.-A.). 5. Université de Paris, Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, France (A.S.-M.).
Abstract
BACKGROUND: Aortic pulse wave velocity is a noninvasive measure of aortic stiffness and arterial aging. Its current value in cardiovascular risk estimation practice is unknown. We aimed to establish whether aortic pulse wave velocity identified individuals with higher risk of incident major adverse cardiovascular events and improved performance of the American Heart Association/American College of Cardiology atherosclerotic cardiovascular disease risk score. METHODS: This prospective analysis included 3837 Whitehall II cohort participants screened in 2008 to 2009, and followed for 11.7 years (mean=10.3, SD=1.81), without history of stroke, myocardial infarction, or coronary heart disease. RESULTS: Mean age of the sample was 65.0 years (SD=5.6), 2831 participants (73.8%) were male and mean atherosclerotic cardiovascular disease risk score was 13.8%. At the end of follow-up, 411 individuals (10.7%) had suffered a major cardiovascular event. Those in the highest aortic pulse wave velocity quartile were at high risk (hazard ratio, 2.99 [95% CI, 2.25-3.97]) and reached the threshold for statin medication (7.5% risk) after 5 years whereas others reached it after 10 years (difference P<0.001). The addition of aortic pulse wave velocity to the risk score improved the C statistic (0.68 versus 0.67, P=0.03) and net reclassification index (4.6%, P=0.04 and 11.3%, P=0.02). CONCLUSIONS: Our results show that aortic stiffness predicted major adverse cardiovascular events in a cohort of elderly individuals, improving the performance of a widely used cardiovascular disease risk estimator. Aortic pulse wave velocity measurement is scalable, radiation-free, and easy to perform. Further studies on its applicability in cardiovascular disease risk assessment in primary care settings are needed.
BACKGROUND: Aortic pulse wave velocity is a noninvasive measure of aortic stiffness and arterial aging. Its current value in cardiovascular risk estimation practice is unknown. We aimed to establish whether aortic pulse wave velocity identified individuals with higher risk of incident major adverse cardiovascular events and improved performance of the American Heart Association/American College of Cardiology atherosclerotic cardiovascular disease risk score. METHODS: This prospective analysis included 3837 Whitehall II cohort participants screened in 2008 to 2009, and followed for 11.7 years (mean=10.3, SD=1.81), without history of stroke, myocardial infarction, or coronary heart disease. RESULTS: Mean age of the sample was 65.0 years (SD=5.6), 2831 participants (73.8%) were male and mean atherosclerotic cardiovascular disease risk score was 13.8%. At the end of follow-up, 411 individuals (10.7%) had suffered a major cardiovascular event. Those in the highest aortic pulse wave velocity quartile were at high risk (hazard ratio, 2.99 [95% CI, 2.25-3.97]) and reached the threshold for statin medication (7.5% risk) after 5 years whereas others reached it after 10 years (difference P<0.001). The addition of aortic pulse wave velocity to the risk score improved the C statistic (0.68 versus 0.67, P=0.03) and net reclassification index (4.6%, P=0.04 and 11.3%, P=0.02). CONCLUSIONS: Our results show that aortic stiffness predicted major adverse cardiovascular events in a cohort of elderly individuals, improving the performance of a widely used cardiovascular disease risk estimator. Aortic pulse wave velocity measurement is scalable, radiation-free, and easy to perform. Further studies on its applicability in cardiovascular disease risk assessment in primary care settings are needed.
Authors: Johan Sundström; Liisa Byberg; Rolf Gedeborg; Karl Michaëlsson; Lars Berglund Journal: Scand J Public Health Date: 2011-01-26 Impact factor: 3.021
Authors: Eric J Brunner; Martin J Shipley; Daniel R Witte; Archana Singh-Manoux; Annie R Britton; Adam G Tabak; Carmel M McEniery; Ian B Wilkinson; Mika Kivimaki Journal: Hypertension Date: 2011-03-28 Impact factor: 10.190
Authors: Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah Journal: Circulation Date: 2018-11-10 Impact factor: 29.690
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Matthew J Budoff; Rebekah Young; Gregory Burke; J Jeffrey Carr; Robert C Detrano; Aaron R Folsom; Richard Kronmal; Joao A C Lima; Kiang J Liu; Robyn L McClelland; Erin Michos; Wendy S Post; Steven Shea; Karol E Watson; Nathan D Wong Journal: Eur Heart J Date: 2018-07-01 Impact factor: 35.855
Authors: Masaki Okamoto; Martin J Shipley; Ian B Wilkinson; Carmel M McEniery; Carlos A Valencia-Hernández; Archana Singh-Manoux; Mika Kivimaki; Eric J Brunner Journal: Hypertension Date: 2019-08-05 Impact factor: 10.190